Accessibility Menu
Zeo ScientifiX logo

Zeo ScientifiX(OTC) BPSR

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-79%
5 Year-93%
1 Year-10%
1 Month+13%
N/A
Zeo ScientifiX last closing stock price
MetricPriceDate
Last closeUSD 1.322026-08-31
Zeo ScientifiX stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.33%USD 1.442026-08-24
1 month+13.4%USD 1.162026-07-31
3 month-30.53%USD 1.902026-06-02
Year to date-51.29%USD 2.712025-12-31
1 year-10.2%USD 1.472025-08-28
3 year-64.32%USD 3.702023-09-01
5 year-92.59%USD 17.822021-09-01
Since inception-79.38%USD 6.112015-01-20

Zeo ScientifiX Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.99M

Net Income (TTM)

-$3.88M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

BPSR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zeo ScientifiX

Zeo ScientifiX develops therapies for degenerative diseases and regenerative medicine. Its products help doctors treat inflammation and support tissue healing. The company also offers solutions for skin and hair health in clinical and aesthetic settings.

Products and Services

  • Biological Therapeutics: Zofin, an acellular therapy from perinatal sources, targets COVID-19, lung disease, and joint pain. In FY2024, high concentration medical grade biologic product offerings accounted for 42.4% of unit sales.
  • Blood-Derived Biologics: Patient Pure X uses a patient’s own blood to reduce inflammation and aid healing (13.3% of revenue in FY2024).
  • Topical Aesthetic Products: ZEO GROW X, ZEO GROW BOOST, and EXO FOLLICLE FUEL support skin and hair health (57.6% of unit sales in FY2024).
  • Collaborative Haircare: ZEO HAIR GROW, developed with Exotropin, expands into professional haircare markets.
  • Lab Services: Laboratory processing and manufacturing for anti-aging and cellular therapy, serving clinics and healthcare providers.

Growth and Expansion

  • Rebranded from Organicell Regenerative Medicine to Zeo ScientifiX in February 2024.
  • Launched Patient Pure X service platform in FY2024, expanding into blood-derived therapies.
  • Invested in Exotropin (8.9% equity, 2024) to boost skincare and haircare product development.
  • Introduced ZEO HAIR GROW with Exotropin in 2024, entering the professional haircare segment.
  • Expanded sales force and provider network in 2024, with plans for international growth.

What Makes Zeo ScientifiX Stand Out

Zeo ScientifiX combines medical and aesthetic products, reaching both healthcare and beauty markets. Its proprietary processing methods and clinical trials support product differentiation. The company’s flexible sales model and partnerships help broaden its customer base.

Five Things You Need to Know

  • Revenue was $4.62 million in FY2024, up 1.4% from FY2023.
  • Gross profit margin was 81.7% in FY2024, down from 88.9% in FY2023.
  • Net loss was $4.71 million in FY2024, improved from $6.99 million in FY2023.
  • Cash used in operations was $1.45 million in FY2024, a 34% improvement year-over-year.
  • Working capital deficit was $2.12 million as of October 31, 2024.

Bottom Line

Zeo ScientifiX has shifted from a single focus to a broader mix of medical and aesthetic products. The company faces financial and regulatory challenges but continues to diversify and adapt its offerings.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

20

CEO

Ian T. Bothwell

Website

www.zeoscientifix.com

Headquarters

Miami, FL 33140, US

BPSR Financials

Key Financial Metrics (TTM)

Gross Margin

81.52%

Operating Margin

-59.10%

Net Income Margin

-55.59%

Return on Equity

455.87%

Return on Capital

N/A

Return on Assets

-99.95%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$5.70M

Operating Income

-$4.13M

EBITDA

$2.67M

Operating Cash Flow

-$1.25M

Capital Expenditure

-$101.00K

Free Cash Flow

-$1.35M

Cash & ST Invst.

$1.85M

Total Debt

$96.00K

Zeo ScientifiX Performance Analysis

Zeo ScientifiX annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-10-31USD 6,491,00816.0%
20232023-10-31USD 4,558,278-29.8%
20242024-10-31USD 4,620,0001.4%
20252025-10-31USD 5,199,00012.5%
Zeo ScientifiX sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-3113.7%
Q42025-10-3126.6%
Q12026-01-31-12.6%
Q22026-04-3078.5%
Zeo ScientifiX annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-10-31USD -1.56-35.0%
20232023-10-31USD -0.99-36.4%
20242024-10-31USD -0.74-25.3%
20252025-10-31USD -0.8616.0%
Zeo ScientifiX sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-31-45.5%
Q42025-10-3162.5%
Q12026-01-31N/A
Q22026-04-3083.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$2.58M

+124.6%

Gross Profit

$2.06M

+130.1%

Gross Margin

79.62%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

18

N/A

Net Income

-$145.00K

+89.6%

EBITDA

$19.00K

+101.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.85M

+240.6%

Total Debt

$96.00K

-5.9%

Accounts Receivable

$276.00K

+2200.0%

Inventory

$686.00K

+191.9%

Long Term Debt

$63.00K

-23.2%

Short Term Debt

$33.00K

+65.0%

Return on Assets

-99.95%

N/A

Return on Invested Capital

-5.33%

N/A

Free Cash Flow

-$202.00K

-41.3%

Operating Cash Flow

-$138.00K

+3.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCELOrganicell Regenerative Medicine, Inc.
$2.74-0.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About BPSR

What is the current price of Zeo ScientifiX?

Zeo ScientifiX is trading at N/A per share.

What is the 52-week range for Zeo ScientifiX?

Over the past 52 weeks, Zeo ScientifiX has traded between N/A and N/A.

How much debt does Zeo ScientifiX have?

As of the most recent reporting period, Zeo ScientifiX reported total debt of $360.00K.

How much cash does Zeo ScientifiX have on hand?

Zeo ScientifiX reported $1.85M in cash and cash equivalents in its most recent financial results.

What is Zeo ScientifiX’s dividend yield?

Zeo ScientifiX does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services